Literature DB >> 28879555

Effects of photodynamic therapy plus intravitreal aflibercept with subtenon triamcinolone injections for aflibercept-resistant polypoidal choroidal vasculopathy.

Dan Călugăru1, Mihai Călugăru2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28879555     DOI： 10.1007/s00417-017-3797-4

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  10 in total

1.  Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes.

Authors:  Sylvie Julien; Antje Biesemeier; Tatjana Taubitz; Ulrich Schraermeyer
Journal:  Br J Ophthalmol       Date:  2014-01-23       Impact factor: 4.638

2.  Comments to: Clinical experience of switching anti-VEGF therapy from ranibizumab to aflibercept in age-related choroidal neovascularization.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Eur J Ophthalmol       Date:  2017-05-11       Impact factor: 2.597

3.  Long-Term Results of Pro Re Nata Regimen of Aflibercept Treatment in Persistent Neovascular Age-Related Macular Degeneration.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Am J Ophthalmol       Date:  2016-11-11       Impact factor: 5.258

4.  Comparison of Time to Retreatment and Visual Function Between Ranibizumab and Aflibercept in Age-Related Macular Degeneration.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Am J Ophthalmol       Date:  2016-12-05       Impact factor: 5.258

5.  Protective effect of intravitreal bevacizumab and sub-tenon triamcinolone acetonide against occlusion of choriocapillaris induced by photodynamic therapy.

Authors:  Ryo Mukai; Shoji Kishi; Taku Sato; Goro Watanabe; Hidetaka Matsumoto
Journal:  Ophthalmologica       Date:  2010-02-25       Impact factor: 3.250

6.  Choroidal Thickness Changes After Intravitreal Antivascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration: Ranibizumab Versus Aflibercept.

Authors:  Magda Gharbiya; Filippo Cruciani; Cesare Mariotti; Francesca Grandinetti; Marco Marenco; Vittorio Cacace
Journal:  J Ocul Pharmacol Ther       Date:  2015-06-03       Impact factor: 2.671

7.  Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy.

Authors:  Seongyong Jeong; Min Sagong
Journal:  Br J Ophthalmol       Date:  2016-09-05       Impact factor: 4.638

8.  INTRAVITREAL DEXAMETHASONE IMPLANT AS ADJUVANT TREATMENT FOR BEVACIZUMAB- AND RANIBIZUMAB-RESISTANT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Prospective Pilot Study.

Authors:  Anita Barikian; Haytham Salti; Ammar Safar; Ziyad R Mahfoud; Ziad F Bashshur
Journal:  Retina       Date:  2017-07       Impact factor: 4.256

9.  Effects of photodynamic therapy plus intravitreal aflibercept with subtenon triamcinolone injections for aflibercept-resistant polypoidal choroidal vasculopathy.

Authors:  Tsutomu Sakai; Noriko Kato; Masaomi Kubota; Hiroshi Tsuneoka
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-06-11       Impact factor: 3.117

10.  Indocyanine green angiographic and optical coherence tomographic findings support classification of polypoidal choroidal vasculopathy into two types.

Authors:  Akiyuki Kawamura; Mitsuko Yuzawa; Ryusaburo Mori; Miho Haruyama; Koji Tanaka
Journal:  Acta Ophthalmol       Date:  2013-07-15       Impact factor: 3.761
  10 in total
  1 in total

1.  The fate of eyes with wet AMD beyond 4 years of anti-VEGF therapy.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-05-07       Impact factor: 3.117
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.